ISSN (Online) = 2522-6754 ISSN (Print) = 2522-6746
WORLD JOURNAL OF BIOLOGY AND BIOTECHNOLOGY
Review Manuscript www.sciplatform.com

Review; Role of epigenetics in cancer

[a,c] **Hafiz Ghulam Muhu-Din Ahmed*, [b] Aziz Ullah , [c] Abdul Malik**
[a] University of Central Punjab, Department of Botany, Punjab Group of Colleges, Bahawalpur, Pakistan,
[b] Department of Plant Breeding and Genetics, College of Agriculture, University of Sargodha, Pakistan,
[c] Department of Plant Breeding and Genetics, Sub Campus Burewala Vehari, University of Agriculture Faisalabad, Pakistan.

Authors' Contribution	**Ahmed, H. G., A. Ullah& A. Malik** contributed equally in the preparation of the manuscript
Article History	***Corresponding email address**: ahmedbreeder@gmail.com **Received: 20 March 2020, Revised: 26 June 2020, Accepted: 01 July 2020, Published Online: 13 July 2020**

ABSTRACT

The epigenetic alterations are central to numerous human diseases, counting cancer. Typically, cancer has been seen as a hereditary infection, and it is presently getting to be clear that the onset of cancer is gone before by epigenetic anomalies. Examiners within the quickly growing field of epigenetics have recorded broad genomic reconstructing in cancer cells, counting methylation of deoxyribonucleic acid (DNA), chemical alteration of the histone proteins, and RNA-dependent control. Recognizing that carcinogenesis includes both hereditary and epigenetic alterations have driven to distant better an understanding of the molecular pathways that oversee the advancement of cancer and to changes in diagnosing and foreseeing the result of different sorts of cancer. Thinks about of the mechanism (s) of epigenetic control and its reversibility have brought about within the recognizable proof of novel targets which will be valuable in creating unused methodologies for the avoidance and treatment of cancer. Cancer is the appearance of both hereditary and epigenetic adjustments. In spite of the fact that cancer start and movement is overwhelmingly driven by procured hereditary modifications, it is getting to be clear that microenvironment mediated epigenetic annoyances play critical parts in neoplastic advancement. Epigenetics is characterized as heritable changes in quality expression, movement and expression that happen without change in DNA arrangements but which are adequately capable to control the flow of quality expression. The key forms that are mindful for epigenetic control are DNA methylation, adjustments in chromatin (covalent adjustment of center histones), nucleosome situating (physical modification), and post-transcriptional quality direction by noncoding RNA (micro-RNAs). A number of well characterized epigenetic adjustments are connected to distorted quality capacities and modified designs of quality expression that play basic parts within the patho-biology of cancer.

Key word: Genetic; cancer; DNA; biotechnology; disease; histone.

INTRODUCTION: Epigenetics implies "above genetics". C.H. Waddington coined the term epigenetics to cruel over or in addition. All the hereditary adjustments barring changes within the original DNA sequence (Jablonka and Raz, 2009). Modification incorporates including atoms like methyl bunches, to the DNA. This changes the appearance and structure of DNA, which modify appear that quality can associate with the translating sequences within the cell's core (Esteller, 2008). Epigenetic alteration turns qualities on or off, which expects or grants the quality to form a protein. One sort of change is DNA can offer help recognize the quality copy obtained from the mother or the one from the father (Kinnaird *et al.*, 2016; Bennett and Licht, 2018). The primary lesson is DNA methylation, in which the DNA is adjusted by a number of DNA methyltransferases (DNMTs) (Reik, 2007). DNA methylation happens at the 5-carbon (C5) position of cytosine bases that are found 5′ to a guanosine base in a CpG dinucleotide (Daxinger and Whitelaw, 2010). The methylation of DNA has different parts in cellular forms, counting direction of quality expression. The moment course of epigenetic legacy includes RNAs, which within the shape of either noncoding RNA (Xist) or RNA obstructions (RNAi) can keep up the quality translation state in a heritable way (Ahmed *et al.*, 2020). The epigenetic data comprises histone (chromatin) alterations that include post-translational checking of histones. These incorporate acetylation and methylation of preserved lysine buildups on the amino-terminal parcels (tails) of histones (5). A number of interesting disclosures have driven to a concept known as the 'histone code' (5–7). This speculation hypothesizes that diverse histone modifications generate a code that's perused by cellular machineries. This code, hence may manage useful results by balancing diverse DNA-based forms, such as quality translation and DNA repair (Roberti *et al.*, 2019; Villanueva *et al.*, 2020).

Epigenetics is included in various commonplace cellular shapes. Consider the truth that our cells all have the same DNA, but our bodies contain various different sorts of cells: neurons, liver cells, pancreatic cells, ignitable cells, and others (Reik, 2007). How can this be? In brief, cells, tissues, and organs differentiate since they have certain sets of qualities that are "turned on" or communicated, as well as other sets that are "turned off" or curbed. Epigenetic calming is one way to turn qualities off, and it can contribute to differential expression. Quieting might as well clarify, in parcel, why innate twins are not phenotypically undefined. In development, epigenetics is crucial for X-chromosome inactivation in female warm blooded animals, which is essential so that females do not have twice the number of X-chromosome quality things as folks. In this way, the centrality of turning qualities off through epigenetic changes is expeditiously clear. Within cells, there are three frameworks that can connected with each other to quiet qualities: DNA methylation, histone alterations, and RNA-associated silencing (Park and Han, 2019; Roberti *et al.*, 2019). Cancer is one of the foremost common human maladies. It is long known that transformations in key controller qualities are trademarks of all

cancer sorts. Separated from these classical genetic pathways there's increasingly prove that moreover epigenetic modifications are vitally included in tumorigenesis (Baylin and Herman, 2000).

Role of aberrant DNA methylation in cancer: DNA methylation is a compound procedure that adds a methyl gathering to DNA. It is exceptionally explicit and consistently occurs in an area where a cytosine nucleotide is situated beside a guanine nucleotide that is connected by a phosphate; this is known as a CpG site. The CpG destinations are methylated by one of three chemicals called DNA methyltransferases (DNMTs) (Luo *et al.*, 2014). Embeddings methyl bunches changes the appearance and structure of DNA, adjusting a quality's associations with the hardware inside a cell's core that is required for interpretation. DNA methylation is utilized in certain qualities to separate which quality duplicate is acquired from the dad and which quality duplicates is acquired from the mother, a marvel known as engraving. Distorted DNA methylation is found in two particular shapes: hypermethylation and hypo-methylation. DNA hypermethylation is the foremost considered epigenetic alter to date, and is found in all sorts of cancer. Hypermethylation regularly happens in CpG islands and is related to quality inactivation (Strathdee and Brown, 2002; Kaz *et al.*, 2007). Although the misfortune of DNA methylation was the primary epigenetic change recognized in cancer, worldwide hypomethylation has been ignored in support of quality promoter-associated hypermethylation. In any case, later considers have appeared that worldwide hypomethylation is found in essentially all human cancers. In spite of the fact that the exact component by which the worldwide misfortune of DNA methylation contributes to the neoplastic prepare is obscure, it is accepted that it may act through acceptance of chromosomal precariousness and actuation of cellular proto-oncogenes (Lan *et al.*, 2020; Shahkarami *et al.*, 2020).

Role of histone modifications in cancer: Histones are proteins that are the fundamental components of chromatin, which is the complex of DNA and proteins that makes up chromosomes. Histones act as a spool around which DNA can wind. When histones are balanced after they are deciphered into protein (i.e., post-translation alteration), they can affect how chromatin is organized, which, in turn, can choose whether the related chromosomal DNA will be deciphered. In case chromatin isn't in a compact outline, it is energetic, and the related DNA can be deciphered (Chervona and Costa, 2012). Then again, on the off chance that chromatin is condensed (making a complex called heterochromatin), at that point it is idle, and DNA interpretation does not happen. There are two fundamental ways histones can be modified (1) Acetylation 2) Methylation. These are chemical shapes that incorporate either an acetyl or methyl bunch, independently, to the amino destructive lysine that's found inside the histone. Acetylation is as a run the show related with energetic chromatin, while deacetylation is for the foremost portion related with heterochromatin (Sawan and Herceg, 2010). On the other hand, histone methylation can be a marker for both energetic and inactive areas of chromatin. For case, methylation of a particular lysine (K9) on a specific histone (H3) that marks noiseless DNA is broadly scattered all through heterochromatin (Calcagno *et al.*, 2019). More often than not the sort of epigenetic change that's tried and true for the inactivated X chromosome of females. In separate, methylation of a particular lysine (K4) on the same histone (H3) can be a marker for energetic qualities (Zhao and Shilatifard, 2019; Zucchetti *et al.*, 2019).

Noncoding RNAs: Noncoding RNAs were at first famous to perform catalytic capacities in encouraging RNA joining, but it was afterward recognized that they take part within the epigenetic wonder of posttranscriptional quality adjustment (Prajapati *et al.*, 2019). They are too known as nonprotein coding RNA or microRNA, and they are 21–23 nucleotides in length. Roughly 1,000 miRNA qualities have been computationally anticipated within the human genome, with each miRNA focusing on different protein coding transcripts (Henshall, 2020). In spite of the fact that miRNA are imperative to typical cell physiology their misexpression has been connected to carcinogenesis, and miRNA profiles are presently being utilized to classify human cancers. The impact of miRNA on the epigenetic apparatus and the complementary epigenetic direction of miRNA expression propose that its deregulation amid carcinogenesis has critical suggestions for worldwide direction of epigenetics and cancer (Vafadar *et al.*, 2019; Ahmed *et al.*, 2020; Henshall, 2020). A few points by point and enlightening reviews of the affiliation between miRNA and cancer are accessible described by scientists (Ullah *et al.*, 2020).

Epigenetic switching in cancer: It is clear that discrete hereditary modifications in neoplastic cells alone cannot clarify multistep carcinogenesis whereby tumor cells are able to precise different phenotypes amid the complex stages of tumor advancement and movement (Sharma *et al.*, 2010; Albrengues *et al.*, 2015). In truth, cancer cells have a changed epigenotype compared with the tissues from which they emerge. The epigenetic switch is characterized by changes within the level and arrangement of DNA methylation and histone adjustment, and these changes impact the phenotype of the neoplastic cells (Iliopoulos *et al.*, 2010). Numerous cancer cells procure changed levels of expression of epigenetic chemicals, but the items of their response don't coordinate the phenotype, proposing that there are other components influencing their movement. For a few decades, it has been known that tumor cells have a worldwide hypomethylated genome, whereas at the same time central cytosine methylation has expanded in particular places of the genome (Hitchler and Domann, 2009). In ordinary cells, CpGs inside monotonous DNA components and coding districts of the qualities are methylated, though in tumor cells LINE-1 rehashes, obsequious DNA, and decently rehashed DNA groupings ended up unmethylated, though qualities containing CpG clusters ended up hypermethylated, rendering them transcriptionally noiseless (Aran *et al.*, 2013).

Epigenetic alterations in cancer: Epigenetic alterations in cancer may too influence the solidness of the genome, giving a connect between the organization of the genome and its replication and repair. Much of the expressive work has illustrated the nature of such changes; in any case, the exact cause of the epigenetic switch in cancer is still tricky (Alves-Fernandes and Jasiulionis, 2019). In human cancers, unusual epigenomics are known to contribute to different stages of neoplastic improvement counting start, advancement, intrusion, metastasis, and chemotherapy resistance. It was as of late proposed that more than 300 qualities and quality items

are epigenetically changed in different human cancers, and these modifications have been connected to proliferative changes, cellular atypia, dysplasia, carcinoma in situ, intrusive danger, metastatic threat, and therapy-resistant threat. Epigenetic hushing of qualities can influence cancer at different stages (Miozzo *et al.*, 2015). The epigenetic changes in quality expression and their pathologic relationship could be a result of covering changes in qualities expression, but a few of them may be related to specific stages of cancer improvement. For illustration, the quality that encodes the cell cycle inhibitor p16INK4A and the DNA repair qualities MLH1 and BRCA1 are a few helpless qualities that experience early methylation-associated hushing that relates with neoplastic change. A few other qualities such as MLH1, VHL, WRN, and BRCA1 that is inactivated by CpG island hypermethylation in changed cells have anti-proliferative parts and in numerous occasions, there are familial cancer cases with related germ-line-like transformations in these qualities. In breast and prostate cancer, the RASSF1A promoter is habitually methylated, and moreover GSTP1 is methylated within the neoplastic cells of more than 90% of cases of prostate cancer. These perceptions bolster the concept that epigenetic changes can advance malignant change (Sadikovic *et al.*, 2008; Deng *et al.*, 2010; Miozzo *et al.*, 2015).

The forceful cancer phenotype has moreover been appeared to be controlled, in portion, by epigenetic components. Metastatic and therapy-resistant behaviors of cells include affiliations between hereditary and epigenetic occasions and modifications in different pathways that contribute to far off metastasis (Maradeo and Cairns, 2011). The administrative systems that work at different level cause changes in quality expression in both tumor and have cells, affecting translation, interpretation, methylation, and a huge number of other forms. The start of these occasions is the result of the impedance of a huge number of tumor silencer qualities that have the capacity to trigger pro-angiogeneic and metastatic properties in influenced threatening cells. For case, down regulation of the angiogenesis inhibitor TSP1 and NM23, which is encoded by nonmetastatic cells, NME1, NME2, and MKK4, is curbed during this process. Extra qualities that are deregulated in cancer are the tissue inhibitor of metalloproteinases such as TIMP3 (promoter hypermethylation amid cancer), which ties to the VEGF-2 and represses angiogenesis (Okugawa *et al.*, 2015). A few other qualities that take an interest in metastasis are uPA, calcium official proteins, and S100P, which encourages tissue intrusion and is related to a destitute guess in breast and prostate cancers. Upregulation of these qualities happens due to hypomethylation and unmasking of the promoter, which connects with the destitute clinical result (Nelson *et al.*, 2009; Muñoz *et al.*, 2012).

Amid metastasis the epigenetic demonstrate proposed is that have microenvironment applies a beginning inhibitory limitation to tumor development, which is taken after by speeding up of tumor movement through complex "cell-matrix" intuitive. For illustration distinctive epigenetic changes in refined epithelial and myoepithelial cells and in stromal fibroblasts from typical breast tissue and breast carcinomas, recommending that abnormal epigenomics within the stroma are one of a kind and discrete from their related carcinoma cells (Feinberg *et al.*, 2006; Valdés-Mora and Stirzaker, 2018). Scientists inspected five qualities, out of them three (PRDM14, HOXD4, and CDC42EP5) were found to be methylated in carcinoma cells, while estrogen receptor PGR and 17β-estradiol metabolizing chemical HSD17B4 are concomitantly methylated within the stromal tissue. Besides, the signaling pathway driving to hypermethylation of the CST6 quality is initiated by the enacted serine/threonine kinase Akt1 pathway. Enactment of Akt1 signaling causes DNA methylation conjointly initiates DNA methyltransferase and quells histone alterations to the promoter of CST6, an occasion that contributes to epigenetic hushing. These occasions outline how epigenetic occasions impact cancer advancement and movement (Rokavec *et al.*, 2016; Rokavec *et al.*, 2017).

CONCLUSION: The significance of epigenetics in cancer has been recognized and intrigued within the field has developed significantly over the final few a long time. Later progresses in epigenomic approaches permit mapping of the methylation/acetylation state and miRNA levels within the genome with well precision, which can offer assistance within the recognizable proof of biomarkers for different infections. An understanding of connect between epigenetic deregulation and cancer will offer assistance in planning superior treatment procedures. Furthermore, the inborn reversibility of epigenetic modifications speaks to an energizing opportunity for the improvement of novel methodologies for cancer prevention.

CONFLICT OF INTEREST: Authors have no conflict of interest.

REFERENCES:

Ahmed, H. G. M.-D., S. Shaukat, I. Kousar, M. Rafiq, M. Ilyas, A. Ullah and K. Buksh, 2020. Gene silencing by double stranded ribonucleic acid (RNA). World journal of biology and biotechnology, 5(1): 41-44.

Albrengues, J., T. Bertero, E. Grasset, S. Bonan, M. Maiel, I. Bourget, C. Philippe, C. H. Serrano, S. Benamar and O. Croce, 2015. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nature communications, 6(1): 1-15.

Alves-Fernandes, D. K. and M. G. Jasiulionis, 2019. The role of sirt1 on DNA damage response and epigenetic alterations in cancer. International journal of molecular sciences, 20(13): 3153.

Aran, D., S. Sabato and A. Hellman, 2013. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome biology, 14(3): 1-14.

Baylin, S. B. and J. G. Herman, 2000. DNA hypermethylation in tumorigenesis: Epigenetics joins genetics. Trends in genetics, 16(4): 168-174.

Bennett, R. L. and J. D. Licht, 2018. Targeting epigenetics in cancer. Annual review of pharmacology and toxicology, 58: 187-207.

Calcagno, D. Q., F. Wisnieski, E. R. d. S. Mota, S. B. Maia de Sousa, J. M. Costa da Silva, M. F. Leal, C. O. Gigek, L. C. Santos, L. T. Rasmussen and P. P. Assumpção, 2019. Role of histone acetylation in gastric cancer: Implications of dietetic compounds and clinical perspectives. Epigenomics, 11(3): 349-362.

Chervona, Y. and M. Costa, 2012. Histone modifications and cancer: Biomarkers of prognosis? American journal of cancer research, 2(5): 589.

Daxinger, L. and E. Whitelaw, 2010. Transgenerational epigenetic inheritance: More questions than answers. Genome research, 20(12): 1623-1628.

Deng, D., Z. Liu and Y. Du, 2010. Epigenetic alterations as cancer diagnostic, prognostic, and predictive biomarkers. In:

Advances in genetics. Elsevier: pp: 125-176.
Esteller, M., 2008. Epigenetics in cancer. New England journal of medicine, 358(11): 1148-1159.
Feinberg, A. P., R. Ohlsson and S. Henikoff, 2006. The epigenetic progenitor origin of human cancer. Nature reviews genetics, 7(1): 21-33.
Henshall, D. C., 2020. Epigenetics and noncoding rna: Recent developments and future therapeutic opportunities. European journal of paediatric neurology, 24: 30-34.
Hitchler, M. J. and F. E. Domann, 2009. Metabolic defects provide a spark for the epigenetic switch in cancer. Free radical biology and medicine, 47(2): 115-127.
Iliopoulos, D., S. A. Jaeger, H. A. Hirsch, M. L. Bulyk and K. Struhl, 2010. Stat3 activation of mir-21 and mir-181b-1 via pten and cyld are part of the epigenetic switch linking inflammation to cancer. Molecular cell, 39(4): 493-506.
Jablonka, E. and G. Raz, 2009. Transgenerational epigenetic inheritance: Prevalence, mechanisms, and implications for the study of heredity and evolution. The Quarterly review of biology, 84(2): 131-176.
Kaz, A., Y. H. Kim, S. Dzieciatkowski, H. Lynch, P. Watson, M. Kay Washington, L. Lin and W. M. Grady, 2007. Evidence for the role of aberrant DNA methylation in the pathogenesis of lynch syndrome adenomas. International journal of cancer, 120(9): 1922-1929.
Kinnaird, A., S. Zhao, K. E. Wellen and E. D. Michelakis, 2016. Metabolic control of epigenetics in cancer. Nature reviews cancer, 16(11): 694-707.
Lan, L., H. Cao, W. Chi, W. Meng, L. Zhao, W. Cui and B. Wang, 2020. Aberrant DNA hypermethylation-silenced linc00886 gene accelerates malignant progression of laryngeal carcinoma. Pathology-research and practice: 152877.
Luo, Y., M. Yu and W. M. Grady, 2014. Field cancerization in the colon: A role for aberrant DNA methylation? Gastroenterology report, 2(1): 16-20.
Maradeo, M. E. and P. Cairns, 2011. Translational application of epigenetic alterations: Ovarian cancer as a model. FEBS letters, 585(13): 2112-2120.
Miozzo, M., V. Vaira and S. M. Sirchia, 2015. Epigenetic alterations in cancer and personalized cancer treatment. Future Oncology, 11(2): 333-348.
Muñoz, P., M. S. Iliou and M. Esteller, 2012. Epigenetic alterations involved in cancer stem cell reprogramming. Molecular oncology, 6(6): 620-636.
Nelson, W. G., A. M. De Marzo and S. Yegnasubramanian, 2009. Minireview: Epigenetic alterations in human prostate cancers. Endocrinology, 150(9): 3991-4002.
Okugawa, Y., W. M. Grady and A. Goel, 2015. Epigenetic alterations in colorectal cancer: Emerging biomarkers. Gastroenterology, 149(5): 1204-1225. e1212.
Park, J. W. and J.-W. Han, 2019. Targeting epigenetics for cancer therapy. Archives of pharmacal research, 42(2): 159-170.
Prajapati, B., M. Fatma, P. Maddhesiya, M. K. Sodhi, M. Fatima, T. Dargar, R. Bhagat, P. Seth and S. Sinha, 2019. Identification and epigenetic analysis of divergent long non-coding RNAs in multilineage differentiation of human neural progenitor cells. RNA biology, 16(1): 13-24.
Reik, W., 2007. Stability and flexibility of epigenetic gene regulation in mammalian development. Nature, 447(7143): 425-432.
Roberti, A., A. F. Valdes, R. Torrecillas, M. F. Fraga and A. F. Fernandez, 2019. Epigenetics in cancer therapy and nanomedicine. Clinical epigenetics, 11(1): 1-18.
Rokavec, M., D. Horst and H. Hermeking, 2017. Cellular model of colon cancer progression reveals signatures of mrnas, mirna, lncrnas, and epigenetic modifications associated with metastasis. Cancer research, 77(8): 1854-1867.
Rokavec, M., M. G. Öner and H. Hermeking, 2016. Lnflammation-induced epigenetic switches in cancer. Cellular and molecular life sciences, 73(1): 23-39.
Sadikovic, B., K. Al-Romaih, J. Squire and M. Zielenska, 2008. Cause and consequences of genetic and epigenetic alterations in human cancer. Current genomics, 9(6): 394-408.
Sawan, C. and Z. Herceg, 2010. Histone modifications and cancer. In: Advances in genetics. Elsevier: pp: 57-85.
Shahkarami, S., S. Zoghi and N. Rezaei, 2020. The role of DNA methylation in cancer. In: Cancer immunology. Springer: pp: 491-511.
Sharma, S., T. K. Kelly and P. A. Jones, 2010. Epigenetics in cancer. Carcinogenesis, 31(1): 27-36.
Strathdee, G. and R. Brown, 2002. Aberrant DNA methylation in cancer: Potential clinical interventions. Expert reviews in molecular medicine, 4(4): 1.
Ullah, A., H. G. M.-D. Ahmed, S. W. Hasan and A. Malik, 2020. Revolutions of crispr/cas9 in modern era as genome editing tool. World Journal of Biology and Biotechnology, 5(2): 47-50.
Vafadar, A., Z. Shabaninejad, A. Movahedpour, S. Mohammadi, S. Fathullahzadeh, H. R. Mirzaei, A. Namdar, A. Savardashtaki and H. Mirzaei, 2019. Long non-coding rnas as epigenetic regulators in cancer. Current pharmaceutical design, 25(33): 3563-3577.
Valdés-Mora, F. and C. Stirzaker, 2018. Epigenetic alterations in primary prostate cancer. In: Precision molecular pathology of prostate cancer. Springer: pp: 193-211.
Villanueva, L., D. Álvarez-Errico and M. Esteller, 2020. The contribution of epigenetics to cancer immunotherapy. Trends in Immunology.
Zhao, Z. and A. Shilatifard, 2019. Epigenetic modifications of histones in cancer. Genome biology, 20(1): 1-16.
Zucchetti, B., A. K. Shimada, A. Katz and G. Curigliano, 2019. The role of histone deacetylase inhibitors in metastatic breast cancer. The breast, 43: 130-134.